Skip to main content
Explore URMC

Edward M. Messing, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-8762

Administrative: (585) 275-3345

Office: (585) 275-0998

Fax: (585) 273-1068

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Surgery, Urology


I chose this field because half of all cancers in men – and almost 20% in women – arise in urologic organs and are treated by urologists. Specializing in urologic oncology is a way of helping many people.

Since I believe that an informed patient makes the wisest decisions regarding treatment, I spend much time educating my patients about their disease and options for treatment. My approach to patient care is individualized, both in terms of treatments offered and recommended, and in terms of the patient's and his or her family's goals. Treating bladder, kidney, prostate and testicular cancer are among my areas of expertise. I also hold several research grants and patents related to the field of urologic cancer.

Conditions I Treat:

- Bladder cancer
- Kidney cancer
- Prostate cancer
- Testicular cancer
- Adrenal cancer
- Penile cancer
- Scrotal cancer
- Ureteral cancer
- Urethral cancer

Professional Background

Dr. Messing received his MD degree from New York University in 1972, did his surgery training at NYU-Bellevue Hospital in New York 1972-1974, and his Urology Residency at Stanford University 1974-1978. After 2 years on the faculty at Tulane University, he completed a fellowship in Urologic Oncology at UCLA in 1982. He was on the faculty of the Division of Urology at the University of Wisconsin from 1982-1995, being Director of their Urologic Oncology Program for the last 10 years. He assumed his current
position at the University of Rochester School of Medicine and Dentistry in September 1995. Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney, testicle, penis and other genitourinary organs, carries on extensive research in the basic biology of bladder and prostate cancers, and has been the principal investigator on numerous clinical studies for the detection, prevention and
treatment of genitourinary cancers.


Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.

His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of development and progression of cancers of the bladder, prostate and kidney, and bringing these studies to fruition for the detection, prevention and treatment of these diseases. He has also designed and conducted landmark phase III clinical trials for each of these cancers and has carried out the first
screening trial for bladder cancer in a general population. Important work has included defining the roles of epidermal growth factor (EGF) and its cell surface receptor in urothelial carcinogenesis and progression, investigating polyamine synthesis inhibition as a means to prevent bladder and prostate cancers, in large phase III clinical trials studying DFMO's ability to prevent bladder cancer's recurrence, the timing of androgen deprivation therapy (ADT) in treating regionally advanced completely resected prostate cancer, and the effectiveness of adjuvant alpha interferon for completely resected,
locally extensive, renal cell carcinoma. He has also contributed importantly to trials testing various forms of intravesical therapy for high risk, non-muscle invading bladder cancer, and the value of radiation therapy after prostatectomy for stage pT3 prostate cancer. He has demonstrated the feasibility of screening for bladder cancer (using hematuria reagent strips) and has worked on the development and testing of several molecular markers for the detection of bladder cancer.

Much of the above mentioned work continues, but currently he is also investigating gender disparities in bladder cancer's incidence and outcome. These efforts have ranged from investigations using large, national data bases, to molecular studies in cells and transgenic animal models. Additionally, he along with his basic science collaborators are investigating the preventative and therapeutic roles of nuclear transcription factors, vitamins and related molecules in prevention and treatment of prostate and bladder cancer. Furthermore, his clinical trial work
continues as the study coordinator (PI) of a large phase III clinical trial of immediate post TURBT intravesical instillation therapy for prevention of recurrence of low risk bladder cancer.



  • Urology - American Board of Urology


MD | New York University School of Medicine

Post-doctoral Training & Residency

09/01/1974 - 06/30/1978
Residency in Urology at Stanford University School of Medicine

09/01/1973 - 06/30/1974
Residency in Surgery at Bellevue Hospital Center

09/01/1972 - 06/30/1973
Internship in Surgery at Bellevue Hospital Center

VIEW ALL expand_more


Presidential Citation Award
Sponsor: American Urological Association
Location: San Diego, California

2013 Best of Posters Award - AUA - 2013 Annual Meeting
Sponsor: American Urological Association
Location: San Diego, California

2012 Best of Posters Award – AUA – 2012 Annual Meeting
Sponsor: American Urological Association
Location: Atlanta, Georgia

2010 - Present
2010 Best of Posters Award - AUA - 2010 Annual Meeting
Sponsor: American Urological Association
Location: San Francisco, California

Davey Award
Sponsor: James P. Wilmot Cancer Center
Location: University of Rochester Medical Center

1999 - 1999
CaP Cure Award
Location: Best Clinical Research on Prostate Cancer

1986 - Present
Location: American College of Surgeons

1985 - Present
Sigma Xi
Sponsor: The Scientific Research Society

1984 - 1986
Junior Faculty Clinical Fellow
Sponsor: American Cancer Society

1977 - 1977
First Prize for Clinical Research and the Bill Smart Award for Best Clinical Paper (Interstitial Cystitis)
Location: Northern California Urology Residents Seminar - Stanford, CA

1975 - 1975
Second Prize for Case Reports (Renal Arteriovenous Fistulas)
Location: Northern California Urology Residents Seminar - Davis, CA

1972 - Present
Alpha Omega Alpha
Location: New York University - School of Medicine

1972 - 1972
The Samuel Soifer Memorial Award for Outstanding Work in Urology - 1972
Location: New York University - School of Medicine

1968 - Present
Phil Beta Kappa
Location: University of Chicago

VIEW ALL expand_more

Clinical Trials

A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcome (S1600)

Lead Researcher: Edward M Messing

This randomized phase III trial studies how well nutrition therapy works in improving immune system in patients with bladder cancer that can be removed by surgery. Improving nutrition before and after surgery may reduce the infections and other problems that sometimes occur after surgery.

View Study Details


Patent Title: Pre- and Intra-Operative Imaging of Bladder Cancer
Patent #: 9,089,601
Issue Date: Jul 28, 2015
Country: United States
Invented By: Dragan J Golijanin, Aimee Johnson Henry, Edward M Messing, Jay Reeder, Ronald W Wood

Patent Title: Intraoperative Imaging of Renal Cortical Tumors and Cysts
Patent #: RE45,916
Issue Date: Mar 08, 2016
Country: United States
Invented By: Dragan J Golijanin, Edward M Messing, Ronald W Wood

Patent Title: Intraoperative Imaging of Renal Cortical Tumors and Cysts
Patent #: 8,725,225
Issue Date: May 13, 2014
Country: United States
Invented By: Dragan J Golijanin, Edward M Messing

VIEW ALL expand_more


Journal Articles

Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF. "Identification of extracellular vesicle periostin as a urinary biomarker of muscle invasive bladder cancer progression" . Oncotarget. 2016; Apr 26;7(17):23335-45.

Baack Kukreja JE, Kiernan M, Schempp B, Siebert A, Hontar A, Dolan J, Noyes K, Dozier A, Ghazi A, Rashid HH, Wu G, Messing. "Quality improvement in cystectomy care with enhanced recovery (QUICCER Study)". EMBJU Int. 2016; April 29.

Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S. "Targeting estrogen/estrogen receptor alpha will enhance Bacillus Calmette-Guerin efficacy in bladder cancer" . Oncotarget. 2016; 15doi: 10.18632/oncotarget.8756.

Books & Chapters

Chapter Title: HGT1 Bladder Cancer: Diagnosis and Treatment
Book Title: Bladder Cancer: Diagnosis and Clinical Management.
Author List: Gaya JM, Palou J, Messing EM
Edited By: Lerner S, Sternberg C, Schoenberg M
Published By: Wiley-Blackwell 2015

Chapter Title: Epidemiology and Natural History
Book Title: Bladder Cancer
Author List: Messing EM, Scosyrev E
Edited By: Konety B, Chang S
Published By: Springer 2014

Chapter Title: Bladder Cancer: Epidemiology, risk factors, screening and chemoprevention
Book Title: Essentials and Updates in Urologic Oncology, 1st Edition
Author List: Knopf J, Trivedi D, Messing EM
Published By: Nova Science Publishers, Inc. 2011




Edward M. Messing, M.D., UR Medicine Urology